期刊文献+

曲美他嗪治疗慢性心力衰竭124例临床分析 被引量:4

Clinical analysis of trimetazidine as treatment of chronic heart failure
下载PDF
导出
摘要 目的探讨曲美他嗪治疗冠心病合并慢性心力衰竭的临床疗效和安全性。方法将248例慢性心力衰竭患者按照随机数字表法随机分为观察组和对照组各124例。对照组采用常规治疗,观察组在常规治疗的基础上联合曲美他嗪治疗,治疗6个月后比较两组治疗效果。结果观察组总有效率89.52%,明显高于对照组,组间比较差异有统计学意义(P<0.05);观察组不良反应发生率为6.45%,明显低于对照组,组间差异有统计学意义(P<0.05)。结论在常规治疗的基础上联合应用曲美他嗪治疗慢性心力衰竭,可有效提高疗效,值得临床推广应用。 Objective To study clinical efficacy and safety of trimetazidine on coronary heart disease combined with chronic heart failure.Methods 248 patients with chronic heart failure patients according to random number table method were randomly divided into trial group and control group,each 124 cases.Control group was used by routine treatment,the observation group based on routine treatment combined application of trimetazidine.The treatment effect was observed.Results The total effective rate of observation group was 89.52%,significantly higher than those in the control group(P〈0.05).The adverse reaction of observation group was 6.45%,and adverse reaction rate was significantly lower than that of the control group(P〈0.05).Conclusion Based on routine treatment combined application of trimetazidine on chronic heart failure can effectively enhance the curative effect.
出处 《西部医学》 2012年第8期1551-1552,共2页 Medical Journal of West China
关键词 慢性心力衰竭 曲美他嗪 疗效 不良反应 Chronic heart failure Trimetazidine Curative effect Adverse reaction
  • 相关文献

参考文献5

二级参考文献26

  • 1曲美他嗪Ⅳ期临床试验协作组.曲美他嗪治疗冠心病合并左心功能不全患者的疗效研究[J].中华心血管病杂志,2005,33(9):793-795. 被引量:123
  • 2Schiano P,Gabriel Steg P.Measurement and prevention of myocardial injury during percutaneous coronary intervention.Heart,2007,93:656-657.
  • 3Kantor PF,Lucien A,Kozak R,et al.The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.Circ Res,2000,86:580-588.
  • 4Lavanchy N,Martin J,Rossi A.Anti-ischemic effects of trimetazidine:31P-NMR spectroscopy in the isolated rat heart.Arch Int Pharmacodyn Ther,1987,286:97-110.
  • 5Renaud JF.Internal pH,Na +,and Ca2 + regulation by trimetazidine during cardiac cell acidosis.Cardiovasc Drugs Ther,1988,1:677-686.
  • 6Cuamieri C,Muscari C.Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium.Pharmacology,1993,46:324-331.
  • 7Boucher FR,Hearse DJ,Opie LH.Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts.J Cardiovasc Pharmacol,1994,24:45-49.
  • 8Belcher PR,Drake-Holland AJ,Hynd JW,et al.Effects of trimetazidine on in vivo coronary arterial platelet thrombosis.Cardiovasc Drugs Ther,1993,7:149-157.
  • 9Williams FM,Tanda K,Kus M,et al.Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits.J Cardiovasc Pharmacol,1993,22:828-833.
  • 10Kantor PF,Lucien A,Kozak R,et al.The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial longchain 3-ketoacyl coenzyme A thiolase.Circ Res,2000,86:580-588.

共引文献160

同被引文献33

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部